GLP1R and type 2 diabetes mellitus: In this US nationwide cohort study assessing the risk of AF among more than 200 000 Medicare beneficiaries with type 2 diabetes, after propensity score matching, the initiation of SGLT-2is was associated with an 18% decrease in the risk of AF compared with dipeptidyl peptidase-4 inhibitors and a 10% decrease in the risk of AF compared with glucagon-like peptide-1 receptor agonists.